# Development of Therapeutics for Biodefense and Emerging Infectious Diseases

> **NIH NIH N01** · VENATORX PHARMACEUTICALS, INC. · 2021 · $4,218,337

## Abstract

To support the development of therapeutic products effective against resistant bacterial infections.

## Key facts

- **NIH application ID:** 10373912
- **Project number:** 272201600029C-P00017-9999-1
- **Recipient organization:** VENATORX PHARMACEUTICALS, INC.
- **Principal Investigator:** TIMOTHY HENKEL
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $4,218,337
- **Award type:** —
- **Project period:** 2016-09-23 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10373912

## Citation

> US National Institutes of Health, RePORTER application 10373912, Development of Therapeutics for Biodefense and Emerging Infectious Diseases (272201600029C-P00017-9999-1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10373912. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*